



OUR VISION

Accelerating the case for change in Biologics



Unmet medical needs are not satisfied in world healthcare, and many patients are eagerly looking for solutions. Among them, antibody drugs are the most promising contribution at the present time. However, the development of antibody drugs takes much money and time, which is why the delivery of solutions to patients is delayed.

Therefore, Chitose Biologics will contribute to speed up the development of antibody drugs and reduce manufacturing costs through the provision of Host Cell Engineering & Cell Line Development platforms, and will continue to contribute to the development of pharmaceuticals for “the millennium” in global healthcare.

COMPANY OVERVIEW

| | | |
|----------------------|--|---|
| Company name | Chitose Biologics Corp. |  Nogawa office  The Kanagawa Science Park (KSP) |
| Established | in 2018 | |
| Board of directors | Managing Director CEO Shinya Kojima Director CTO Takayuki Horiuchi Ph.D. Director Tomohiro Fujita Ph.D. |  |
| Shareholders | CHITOSE BIO EVOLUTION PTE. LTD. (Holding Company) | |
| Operation Sites | 3-2-1 , Sakado, Takatsu-ku, Kawasaki Kanagawa, 213-0012, Japan | |
| Contact | +81-44-813-3380 (Same as Chitose Laboratory) info-cb@chitose-bio.com | |
| Business Description | <ul style="list-style-type: none"> Chitose Biologics creates new innovative value by linking technologies created from the Chitose Group Chitose Biologics aims to build a biopharmaceutical manufacturing process for the next generation in collaboration with all stakeholders, using the super cell developed by the Chitose group as its core technology. | |

OUR TECHNOLOGY



Host Cell Engineering & Cell Line Development Platform for Biologics

15+
YEARS
Of Biologics CRO
Experience

30+
PROJECTS
Of Host Cell Engineering
& Cell line development

15+
COMPANIES
Developing
Biologics

Chitose Biologics provides two services,
Disparity Mutagenesis Technology & Cell Line Development Service.




[Overview]

- Host cell engineering technology that can improve traits of host animal cells (CHO, HEK, NS0, SF9).

[Features]

- The only technology in the world that is able to induce unique random mutation efficiently to the large animal cell genome.
- Abundant screening know-hows to fish out cell lines with the desired trait from millions of variant pools.



[Overview]

- Original CHO cell line development platform for biologics (CE&antibody drug & protein drug) manufacturing.


[Features]

- Produce stable and clonal cell banks in 10wks.
- Provide titer of 3-7 g/L for CHO cell lines.
- Used for any host-vector system without gene amplification system.
- In addition to full packaging service, each process (stable pool, RCB) can be provided according to customer's needs.

OUR EXPERIENCE

Disparity Mutagenesis Technology (DMT)

Chitose Laboratory developed our unique mutagenesis technology, the disparity mutagenesis technology (DMT), based on "Disparity Theory of Evolution", which is applicable to industrial animal cell development.



Cell Line Development Platform for biologics

Chitose's CLD platform produces CHO research cell banks from as short as 10 weeks, by high-throughput screening technology, unique single cell sorting based on flow cytometry (FCM) and selection methods of high producing clones during colony formation using fluorescently labeled probe compounds.

